Nomura/Instinet Reiterates Reduce Rating on Alnylam Pharma (ALNY) After Speaking with Management
Tweet Send to a Friend
Nomura/Instinet analyst, Christopher Marai reiterated a Reduce rating and $62.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) after meeting with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
